These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 22704044)

  • 1. Antidepressant-like effects of ecstasy in subjects with a predisposition to depression.
    Majumder I; White JM; Irvine RJ
    Addict Behav; 2012 Oct; 37(10):1189-92. PubMed ID: 22704044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
    Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
    J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.
    Soar K; Turner JJ; Parrott AC
    J Psychopharmacol; 2006 May; 20(3):417-24. PubMed ID: 16574716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recreational ecstasy use and depression.
    Guillot C; Greenway D
    J Psychopharmacol; 2006 May; 20(3):411-6. PubMed ID: 16574715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is recreational ecstasy (MDMA) use associated with higher levels of depressive symptoms?
    Guillot C
    J Psychoactive Drugs; 2007 Mar; 39(1):31-9. PubMed ID: 17523583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users.
    Pirona A; Morgan MJ
    J Psychopharmacol; 2010 Feb; 24(2):175-85. PubMed ID: 19351799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of acute psychotic episode after a single dose of ecstasy].
    Vaiva G; Bailly D; Boss V; Thomas P; Lestavel P; Goudemand M
    Encephale; 2001; 27(2):198-202. PubMed ID: 11407274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subacute effects of ecstasy on mood: an exploration of associated risk factors.
    Scott RM; Hides L; Allen JS; Lubman DI
    J Psychopharmacol; 2013 Jan; 27(1):53-61. PubMed ID: 23095244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study.
    de Win MM; Schilt T; Reneman L; Vervaeke H; Jager G; Dijkink S; Booij J; van den Brink W
    J Psychopharmacol; 2006 Mar; 20(2):226-35. PubMed ID: 16510480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans.
    Huxster JK; Pirona A; Morgan MJ
    J Psychopharmacol; 2006 Mar; 20(2):281-90. PubMed ID: 16510486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences.
    Verheyden SL; Hadfield J; Calin T; Curran HV
    Psychopharmacology (Berl); 2002 Apr; 161(1):23-31. PubMed ID: 11967627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depressive symptomatology in young adults with a history of MDMA use: a longitudinal analysis.
    Falck RS; Wang J; Carlson RG
    J Psychopharmacol; 2008 Jan; 22(1):47-54. PubMed ID: 18187532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender.
    de Win MM; Reneman L; Reitsma JB; den Heeten GJ; Booij J; van den Brink W
    Psychopharmacology (Berl); 2004 May; 173(3-4):376-82. PubMed ID: 14726997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring depressive symptoms among treatment-resistant seizure disorder patients: POMS Depression scale as an alternative to the BDI-II.
    Griffith NM; Szaflarski JP; Szaflarski M; Kent GP; Schefft BK; Howe SR; Privitera MD
    Epilepsy Behav; 2005 Sep; 7(2):266-72. PubMed ID: 16005686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ecstasy (MDMA) and high prevalence psychiatric symptomatology: somatic anxiety symptoms are associated with polydrug, not ecstasy, use.
    Bedi G; Van Dam NT; Redman J
    J Psychopharmacol; 2010 Feb; 24(2):233-40. PubMed ID: 18832429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coping style and ecstasy use motives as predictors of current mood symptoms in ecstasy users.
    Scott RM; Hides L; Allen JS; Lubman DI
    Addict Behav; 2013 Oct; 38(10):2465-72. PubMed ID: 23770644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and correlates of current depressive symptomatology among a community sample of MDMA users in Ohio.
    Falck RS; Wang J; Carlson RG; Siegal HA
    Addict Behav; 2006 Jan; 31(1):90-101. PubMed ID: 15922511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low.
    Curran HV; Travill RA
    Addiction; 1997 Jul; 92(7):821-31. PubMed ID: 9293041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An investigation into the sub-acute effects of ecstasy on aggressive interpretative bias and aggressive mood - are there gender differences?
    Hoshi R; Pratt H; Mehta S; Bond AJ; Curran HV
    J Psychopharmacol; 2006 Mar; 20(2):291-301. PubMed ID: 16510487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is emotional intelligence impaired in ecstasy-polydrug users?
    Craig L; Fisk JE; Montgomery C; Murphy PN; Wareing M
    J Psychopharmacol; 2010 Feb; 24(2):221-31. PubMed ID: 18801831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.